Literature DB >> 18245060

Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.

T Scott Stroup1, John R Geddes.   

Abstract

Randomized controlled trials for antipsychotic drugs have a variety of design features suited to diverse purposes. Efficacy (or explanatory) trials seek to establish if a drug can reduce psychotic symptoms under ideal circumstances. To isolate drug effects, researchers enroll carefully selected patients. Specialized research personnel use rating scales of symptoms that are sensitive to drug effects as the study primary outcomes. Large simple trials (LSTs) are conducted at typical treatment settings with usual clinical personnel and enroll large numbers of participants so small but clinically important differences between treatment options can be detected. LSTs focus narrowly on clearly defined, patient-oriented outcomes. To some extent, practical trials can be conceptualized as hybrids of efficacy and large simple trials. Practical trials provide independent evidence to inform decision makers about the everyday effectiveness of clinically relevant alternative interventions. Practical trial researchers include a heterogeneous population of patients and collect data on a broad range of meaningful health outcomes at many types of practice settings intended to represent usual treatment. The designers of practical trials make trade-offs between internal validity, external validity, the breadth of issues addressed, and the ability to detect small differences. The different objectives of trials should be considered in the interpretation of the complete body of randomized evidence on antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245060      PMCID: PMC2632397          DOI: 10.1093/schbul/sbm156

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  35 in total

1.  A meta-analysis of the efficacy of second-generation antipsychotics.

Authors:  John M Davis; Nancy Chen; Ira D Glick
Journal:  Arch Gen Psychiatry       Date:  2003-06

Review 2.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.

Authors:  J Geddes; N Freemantle; P Harrison; P Bebbington
Journal:  BMJ       Date:  2000-12-02

3.  Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?

Authors:  Jeffrey A Lieberman; T Scott Stroup
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

4.  Approaches to multisite clinical trials: the National Institute of Mental Health perspective.

Authors:  Barry D Lebowitz; Benedetto Vitiello; Grayson S Norquist
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

5.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

6.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

7.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

8.  Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine.

Authors: 
Journal:  BMJ       Date:  2003-09-27

9.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

Authors:  Stephen R Marder; Michelle Kramer; Lisa Ford; Els Eerdekens; Pilar Lim; Mariëlle Eerdekens; Adam Lowy
Journal:  Biol Psychiatry       Date:  2007-06-28       Impact factor: 13.382

View more
  3 in total

1.  Clinical trial design: horses for courses.

Authors:  John R Geddes
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

2.  Critical trial-related criteria in acute schizophrenia studies.

Authors:  Michael Riedel; Stefan Leucht; Eckart Rüther; Max Schmauß; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-07-26       Impact factor: 5.270

3.  Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.

Authors:  Miquel Bernardo; Fernando Rico-Villademoros; Clemente García-Rizo; Rosa Rojo; Ricardo Gómez-Huelgas
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.